| Rafael Pita, MD | |
|
900 N Robert Ave, Arcadia, FL 34266-8712 | |
| (863) 494-3535 | |
| Not Available |
| Full Name | Rafael Pita |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 12 Years |
| Location | 900 N Robert Ave, Arcadia, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427391465 | NPI | - | NPPES |
| 33181 | Other | FL | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | ME127920 (Florida) | Secondary |
| 207Q00000X | Family Medicine | E8958 (Arkansas) | Secondary |
| 207P00000X | Emergency Medicine | ME127920 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Desoto Memorial Hospital | Arcadia, FL | Hospital |
| Hendry Regional Medical Center | Clewiston, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Small Hospital Innovations | 0840415444 | 41 |
| Shi Keys Llc | 2163835513 | 17 |
News Archive
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed a provisional patent application with the United States Patent and Trademark Office for a combination therapy of its lead compound, ORMD-0801 in combination with its oral exenatide formulation, ORMD-0901. There is no such approved combination product available on the market today.
The AstraZeneca HealthCare Foundation's Connections for Cardiovascular Health program today announced it will award nearly $3.7 million in grants to 19 nonprofit organizations dedicated to improving cardiovascular health in local communities.
For an amputee, replacing a missing limb with a functional prosthetic can alleviate physical or emotional distress and mean a return of vocational ability or cosmetics. Studies show, however, that up to 50 percent of hand amputees still do not use their prosthesis regularly due to less than ideal functionality, appearance, and controllability. But Silvestro Micera, of the -cole Polytechnique F-d-rale de Lausanne (EPFL) in Switzerland, is paving the way for new, smart prosthetics that connect directly to the nervous system.
Barr Pharmaceuticals, Inc. today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Endo Pharmaceuticals Inc. in connection with its Opana(R) ER (oxymorphone hydrochloride) extended-release tablets, 5 mg, 10 mg, 20 mg and 40 mg.
› Verified 3 days ago
| Entity Name | Smh Physician Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346295292 PECOS PAC ID: 1355240177 Enrollment ID: O20031231000211 |
News Archive
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed a provisional patent application with the United States Patent and Trademark Office for a combination therapy of its lead compound, ORMD-0801 in combination with its oral exenatide formulation, ORMD-0901. There is no such approved combination product available on the market today.
The AstraZeneca HealthCare Foundation's Connections for Cardiovascular Health program today announced it will award nearly $3.7 million in grants to 19 nonprofit organizations dedicated to improving cardiovascular health in local communities.
For an amputee, replacing a missing limb with a functional prosthetic can alleviate physical or emotional distress and mean a return of vocational ability or cosmetics. Studies show, however, that up to 50 percent of hand amputees still do not use their prosthesis regularly due to less than ideal functionality, appearance, and controllability. But Silvestro Micera, of the -cole Polytechnique F-d-rale de Lausanne (EPFL) in Switzerland, is paving the way for new, smart prosthetics that connect directly to the nervous system.
Barr Pharmaceuticals, Inc. today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Endo Pharmaceuticals Inc. in connection with its Opana(R) ER (oxymorphone hydrochloride) extended-release tablets, 5 mg, 10 mg, 20 mg and 40 mg.
› Verified 3 days ago
| Entity Name | Mid-florida Emergency Physicians, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558630152 PECOS PAC ID: 8426213596 Enrollment ID: O20120625000057 |
News Archive
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed a provisional patent application with the United States Patent and Trademark Office for a combination therapy of its lead compound, ORMD-0801 in combination with its oral exenatide formulation, ORMD-0901. There is no such approved combination product available on the market today.
The AstraZeneca HealthCare Foundation's Connections for Cardiovascular Health program today announced it will award nearly $3.7 million in grants to 19 nonprofit organizations dedicated to improving cardiovascular health in local communities.
For an amputee, replacing a missing limb with a functional prosthetic can alleviate physical or emotional distress and mean a return of vocational ability or cosmetics. Studies show, however, that up to 50 percent of hand amputees still do not use their prosthesis regularly due to less than ideal functionality, appearance, and controllability. But Silvestro Micera, of the -cole Polytechnique F-d-rale de Lausanne (EPFL) in Switzerland, is paving the way for new, smart prosthetics that connect directly to the nervous system.
Barr Pharmaceuticals, Inc. today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Endo Pharmaceuticals Inc. in connection with its Opana(R) ER (oxymorphone hydrochloride) extended-release tablets, 5 mg, 10 mg, 20 mg and 40 mg.
› Verified 3 days ago
| Entity Name | Small Hospital Innovations |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184040560 PECOS PAC ID: 0840415444 Enrollment ID: O20140715000513 |
News Archive
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed a provisional patent application with the United States Patent and Trademark Office for a combination therapy of its lead compound, ORMD-0801 in combination with its oral exenatide formulation, ORMD-0901. There is no such approved combination product available on the market today.
The AstraZeneca HealthCare Foundation's Connections for Cardiovascular Health program today announced it will award nearly $3.7 million in grants to 19 nonprofit organizations dedicated to improving cardiovascular health in local communities.
For an amputee, replacing a missing limb with a functional prosthetic can alleviate physical or emotional distress and mean a return of vocational ability or cosmetics. Studies show, however, that up to 50 percent of hand amputees still do not use their prosthesis regularly due to less than ideal functionality, appearance, and controllability. But Silvestro Micera, of the -cole Polytechnique F-d-rale de Lausanne (EPFL) in Switzerland, is paving the way for new, smart prosthetics that connect directly to the nervous system.
Barr Pharmaceuticals, Inc. today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Endo Pharmaceuticals Inc. in connection with its Opana(R) ER (oxymorphone hydrochloride) extended-release tablets, 5 mg, 10 mg, 20 mg and 40 mg.
› Verified 3 days ago
| Entity Name | L.o.t. Health Services, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619367976 PECOS PAC ID: 0648560573 Enrollment ID: O20160606002526 |
News Archive
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed a provisional patent application with the United States Patent and Trademark Office for a combination therapy of its lead compound, ORMD-0801 in combination with its oral exenatide formulation, ORMD-0901. There is no such approved combination product available on the market today.
The AstraZeneca HealthCare Foundation's Connections for Cardiovascular Health program today announced it will award nearly $3.7 million in grants to 19 nonprofit organizations dedicated to improving cardiovascular health in local communities.
For an amputee, replacing a missing limb with a functional prosthetic can alleviate physical or emotional distress and mean a return of vocational ability or cosmetics. Studies show, however, that up to 50 percent of hand amputees still do not use their prosthesis regularly due to less than ideal functionality, appearance, and controllability. But Silvestro Micera, of the -cole Polytechnique F-d-rale de Lausanne (EPFL) in Switzerland, is paving the way for new, smart prosthetics that connect directly to the nervous system.
Barr Pharmaceuticals, Inc. today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Endo Pharmaceuticals Inc. in connection with its Opana(R) ER (oxymorphone hydrochloride) extended-release tablets, 5 mg, 10 mg, 20 mg and 40 mg.
› Verified 3 days ago
| Entity Name | Shi Keys Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952903536 PECOS PAC ID: 2163835513 Enrollment ID: O20210105000345 |
News Archive
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed a provisional patent application with the United States Patent and Trademark Office for a combination therapy of its lead compound, ORMD-0801 in combination with its oral exenatide formulation, ORMD-0901. There is no such approved combination product available on the market today.
The AstraZeneca HealthCare Foundation's Connections for Cardiovascular Health program today announced it will award nearly $3.7 million in grants to 19 nonprofit organizations dedicated to improving cardiovascular health in local communities.
For an amputee, replacing a missing limb with a functional prosthetic can alleviate physical or emotional distress and mean a return of vocational ability or cosmetics. Studies show, however, that up to 50 percent of hand amputees still do not use their prosthesis regularly due to less than ideal functionality, appearance, and controllability. But Silvestro Micera, of the -cole Polytechnique F-d-rale de Lausanne (EPFL) in Switzerland, is paving the way for new, smart prosthetics that connect directly to the nervous system.
Barr Pharmaceuticals, Inc. today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Endo Pharmaceuticals Inc. in connection with its Opana(R) ER (oxymorphone hydrochloride) extended-release tablets, 5 mg, 10 mg, 20 mg and 40 mg.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rafael Pita, MD 5512 Secluded Oaks Way, Sarasota, FL 34233-5086 Ph: (786) 879-2801 | Rafael Pita, MD 900 N Robert Ave, Arcadia, FL 34266-8712 Ph: (863) 494-3535 |
News Archive
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed a provisional patent application with the United States Patent and Trademark Office for a combination therapy of its lead compound, ORMD-0801 in combination with its oral exenatide formulation, ORMD-0901. There is no such approved combination product available on the market today.
The AstraZeneca HealthCare Foundation's Connections for Cardiovascular Health program today announced it will award nearly $3.7 million in grants to 19 nonprofit organizations dedicated to improving cardiovascular health in local communities.
For an amputee, replacing a missing limb with a functional prosthetic can alleviate physical or emotional distress and mean a return of vocational ability or cosmetics. Studies show, however, that up to 50 percent of hand amputees still do not use their prosthesis regularly due to less than ideal functionality, appearance, and controllability. But Silvestro Micera, of the -cole Polytechnique F-d-rale de Lausanne (EPFL) in Switzerland, is paving the way for new, smart prosthetics that connect directly to the nervous system.
Barr Pharmaceuticals, Inc. today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Endo Pharmaceuticals Inc. in connection with its Opana(R) ER (oxymorphone hydrochloride) extended-release tablets, 5 mg, 10 mg, 20 mg and 40 mg.
› Verified 3 days ago
Dr. Steven Hart Mishkind, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 900 N Roberts Ave, Arcadia, FL 34266 Phone: 863-494-3535 | |
Dr. Victor Delgado, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 900 N Roberts Ave, Emergency Department, Arcadia, FL 34266 Phone: 863-494-3535 |